FATE Q1 2020 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$142M

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-4.4% YoY

Gross Profit

-$27M-1064.1% margin

Operating Income

-$34M-1371.5% margin

Net Income

-$34M-1332.8% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

-10.2%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$28M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$322M

Total Liabilities

$103M

Stockholders' Equity

$219M

Cash & Equivalents

$83M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$3M	-4.4%
Gross Profit	-$27M	-$15M	-77.3%
Operating Income	-$34M	-$20M	-68.7%
Net Income	-$34M	-$20M	-69.6%